Our focus is on neurochemicals acting on the peripheral and central nervous system

We are enthusiastic about neurochemicals acting as agonists or antagonists on G-protein coupled receptors located in the peripheral and central nervous system. Our goal is to address the clinical needs to diagnose and treat the neurological pathologies at the origin of the disease; thus, avoiding a merely systematic treatment and rather stopping or delaying disease progression.

The chemical structure of small molecules is the key for successful drug design and development for both imaging probes and therapeutics. The combined, interdisciplinary knowledge of medicinal chemists, pharmacists and physicians allows drug adjustment and pave the way towards the application of our substances as tools for image-guided therapy.

The bottleneck of the drug development process is the preclinical screening of a compound library, as we still lack substantial methods for a fast and reliable biological assessment. We developed a complex dynamic 3D-cell culture method, which mimics the tissue situation and has the potential to fasten the screening process. Moreover, it conforms with the 3Rs (reduce, replace, refine) rule in animal ethics and will contribute to reduce the number of animals needed in drug testing.

Our main interests lie in

  • Inventive drug development of neurochemicals
  • Innovative drug screening methods
  • Interdisciplinary approaches close to medical application

EANM 2021 Plenary Lecture - Isotopes Past and Future

Missed the EANM 2021 plenary lecture on the availability of medicinal radioisotopes.

You can still watch it here.

News and announcements

1 2
03.12.2021
 

Drug safety is top priority to prevent any event that may cause or lead to inappropriate medication; although, these events continuously occurred throughout history until today. We found that pirenzepine undergoes a scaffold rearrangement from the pharmaceutical active ingredient (API) to a previously uncharacterized benzimidazole. Check out our new publication.

28.11.2021
 

With the Erasmus student Karolina Dzedulionyte from the Departement of Organic Chemistry, we started a new cooperation with the Kaunas University of Technology and we are looking forward to a fruitful ongoing exchange of knowledge and research.

28.11.2021
 

On friday Verena Maisetschläger successfully defended her master thesis "SOP development and standardization of preclinical HPLC methods investigating purity, lipophilicity and stability". We congratulate her and wish her all the best for her future.

24.11.2021
 

Mariella successfully graduated with the master thesis "Preclinical development of potential suptype-selective ligands towards the muscarinic acetylcholine receptor" We wish her all the best for her future.

28.10.2021
 

We are more than happy to be part of the FFG COMET Module uONE in cooperation with CBmed Graz with the title "Microplastic Particles: a Hazard for Human Health?"

11.10.2021
 

We are proud to contribute to the recent EANM guideline on molar activity

1 2